Dementia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2500

Dementia is the loss of mental functions such as thinking, memory, and reasoning that is severe enough to interfere with a person’s daily functioning. Symptoms include memory loss, hallucinations, agitation, personality changes, and difficulty with coordination and motor functions. Risk factors include age, smoking, obesity, high blood pressure, inflammation, and cardiovascular diseases.

The Dementia Drugs in Development market research report provides an overview of the Dementia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Dementia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dementia and features dormant and discontinued projects.

Key Targets in the Dementia Pipeline Drugs Market

Some of the targets in the dementia pipeline drugs market are Microtubule Associated Protein Tau, Acetylcholinesterase, Alpha Synuclein, Amyloid Beta A4 Protein, Glutamate Ionotropic Receptor NMDA Type Subunit, Progranulin, 5-Hydroxytryptamine Receptor 2A, TAR DNA Binding Protein 43, 1 Phosphatidylinositol 3 Phosphate 5 Kinase, and Cannabinoid Receptor 2.

Dementia pipeline drugs market, by targets

Dementia pipeline drugs market, by targets

For more target insights, download a free report sample

Mechanisms of Action in the Dementia Pipeline Drugs Market

Some of the mechanisms of action in the dementia pipeline drugs market are Microtubule Associated Protein Tau Inhibitor, Acetylcholinesterase Inhibitor, Alpha Synuclein Inhibitor, Amyloid Beta A4 Protein Inhibitor, Progranulin Activator, 5-Hydroxytryptamine Receptor 2A Antagonist, TAR DNA Binding Protein 43 Inhibitor, 1 Phosphatidylinositol 3 Phosphate 5 Kinase Inhibitor, Cannabinoid Receptor 2 Agonist, and Glutamate Ionotropic Receptor NMDA Type Subunit Antagonist.

Dementia pipeline drugs market, by mechanisms of action

Dementia pipeline drugs market, by mechanisms of action

For more mechanisms of action insights, download a free report sample

Routes of Administration in the Dementia Pipeline Drugs Market

The routes of administration in the dementia pipeline drugs market are oral, intravenous, subcutaneous, nasal, parenteral, transdermal, intramuscular, intracerebral, intracisternal, and intrathecal.

Dementia pipeline drugs market, by routes of administration

Dementia pipeline drugs market, by routes of administration

For more routes of administration insights, download a free report sample

Molecule Types in the Dementia Pipeline Drugs Market

The molecule types in the dementia pipeline drugs market are small molecule, monoclonal antibody, gene therapy, cell therapy, synthetic peptide, biologic, peptide, conjugate vaccine, recombinant protein, and subunit vaccine.

Dementia pipeline drugs market, by molecule types

Dementia pipeline drugs market, by molecule types

For more molecule type insights, download a free report sample

Key Dementia Pipeline Drugs Market Companies

Some of the key companies in the dementia pipeline drugs market are ADEL Inc, Eisai Co Ltd, AcuraStem Inc, Alkermes Plc, Coya Therapeutics Inc, Merck & Co Inc, P2D Inc, Whan In Pharm Co Ltd, AFFiRiS AG, and Alector Inc.

Dementia pipeline drugs market, by key companies

Dementia pipeline drugs market, by key companies

To know more about key companies, download a free report sample

Market report overview

Targets Microtubule Associated Protein Tau, Acetylcholinesterase, Alpha Synuclein, Amyloid Beta A4 Protein, Glutamate Ionotropic Receptor NMDA Type Subunit, Progranulin, 5-Hydroxytryptamine Receptor 2A, TAR DNA Binding Protein 43, 1 Phosphatidylinositol 3 Phosphate 5 Kinase, and Cannabinoid Receptor 2
Mechanisms of Action Microtubule Associated Protein Tau Inhibitor, Acetylcholinesterase Inhibitor, Alpha Synuclein Inhibitor, Amyloid Beta A4 Protein Inhibitor, Progranulin Activator, 5-Hydroxytryptamine Receptor 2A Antagonist, TAR DNA Binding Protein 43 Inhibitor, 1 Phosphatidylinositol 3 Phosphate 5 Kinase Inhibitor, Cannabinoid Receptor 2 Agonist, and Glutamate Ionotropic Receptor NMDA Type Subunit Antagonist
Routes of Administration Oral, Intravenous, Subcutaneous, Nasal, Parenteral, Transdermal, Intramuscular, Intracerebral, Intracisternal, and Intrathecal
Molecule Types Small Molecule, Monoclonal Antibody, Gene Therapy, Cell Therapy, Synthetic Peptide, Biologic, Peptide, Conjugate Vaccine, Recombinant Protein, and Subunit Vaccine
Key Companies ADEL Inc, Eisai Co Ltd, AcuraStem Inc, Alkermes Plc, Coya Therapeutics Inc, Merck & Co Inc, P2D Inc, Whan In Pharm Co Ltd, AFFiRiS AG, and Alector Inc

Scope

This report provides:

  • A snapshot of the global therapeutic landscape of Dementia (Central Nervous System).
  • Reviews of pipeline therapeutics for Dementia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
  • Descriptive drug profiles for the pipeline products which include product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
  • Reviews of key companies involved in the Dementia (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • Evaluation of Dementia (Central Nervous System) targeted therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA), and molecule type.
  • All the dormant and discontinued pipeline projects.
  • Reviews of the latest news and deals related to pipeline therapeutics for Dementia (Central Nervous System).

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Dementia (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Dementia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

2N Pharma ApS
AbbVie Inc
Acadia Pharmaceuticals Inc
Actinogen Medical Ltd
AcuraStem Inc
Adamed Pharma SA
ADEL Inc
AFFiRiS AG
AgeneBio Inc
AIBIOS Co Ltd
Alector Inc
Alkermes Plc
AlphaCognition Inc
Alterity Therapeutics Ltd
Alzamend Neuro Inc
Amarantus Bioscience Holdings Inc
Anavex Life Sciences Corp
Anhorn Medicines Co Ltd
Annovis Bio Inc
Aphios Corp
Applied Genetic Technologies Corp
Aprinoia Therapeutics Inc
Aptinyx Inc
AriBio
Arkuda Therapeutics Inc
Arvinas Inc
Asahi Kasei Pharma Corp
Asceneuron SA
AskAt Inc
Astrogen Ltd
Athira Pharma Inc
AULBIO Co Ltd
Aurum Biosciences Ltd
Autifony Therapeutics Ltd
Avanir Pharmaceuticals Inc
AviadoBio Ltd
Avineuro Pharmaceuticals Inc
Avrion Therapeutics AG
Axon Neuroscience SE
Axsome Therapeutics Inc
Bioasis Technologies Inc
Biogen Inc
Biom Therapeutics LLC
Biorchestra Co Ltd
BioXcel Therapeutics Inc
CAMP4 Therapeutics Corp
Cellivery Therapeutics Inc
Cellular Biomedicine Group Ltd
Cennerv Pharma (S) Pte Ltd
Cerevel Therapeutics Holdings Inc
ChunLab Inc
Cogentis Therapeutics Inc
Cognition Therapeutics Inc
Cortice Biosciences Inc
Coya Therapeutics Inc
CSPC NBP Pharmaceutical Co Ltd
CuraSen Therapeutics Inc
Cyclerion Therapeutics Inc
Dadang & BIO Co Ltd
Daewoong Pharmaceutical Co Ltd
Denali Therapeutics Inc
DiaMedica Therapeutics Inc
Dongkook Pharmaceutical Co Ltd
Dr. August Wolff GmbH & Co KG Arzneimittel
Echo Pharmaceuticals BV
EIP Pharma LLC
Eisai Co Ltd
Eli Lilly and Co
ENCEFA
Ensol Biosciences Inc
Enterin Inc
EVER Neuro Pharma GmbH
Expansion Therapeutics Inc
Galimedix Therapeutics Ltd
Generian Pharmaceuticals Inc
Gismo Therapeutics Inc
GraySpace Therapeutics Inc
Guangzhou Magpie Pharmaceutical Co Ltd
HanAll Biopharma Co Ltd
Hemostemix Inc
Herophilus
HLB Pharmaceutical Co Ltd
Hyundai Pharma Co Ltd
IGC Pharma LLC
Immungenetics AG
ImStar Therapeutics Inc
Inhibikase Therapeutics Inc
Intra-Cellular Therapies Inc
IntraBio Ltd
Inventage Lab Inc
Ionis Pharmaceuticals Inc
IRLAB Therapeutics AB
Jazz Pharmaceuticals Plc
Johnson & Johnson
KeifeRx LLC
Kogenix Therapeutics Inc
Korea Pharma Co Ltd
Kuano Ltd
Kwang Dong Pharmaceutical Co Ltd
Lachesis Biosciences Ltd
Locanabio Inc
Luye Pharma Group Ltd
MediPost Co Ltd
Merck & Co Inc
Merz Pharma GmbH & Co KgaA
Metro International Biotech LLC
MGC Pharmaceuticals Ltd
MThera Pharma Co Ltd
MYND Life Sciences Inc
Neuramedy Co Ltd
Neurimmune Holding AG
Neurokine Therapeutics
NeuroScientific Biopharmaceuticals Ltd
NeuroTau Inc
Neuvivo Inc
NLS Pharmaceutics AG
Novartis AG
Novo Nordisk AS
Oligomerix inc
Orchard Therapeutics Plc
Oryzon Genomics SA
Otsuka Pharmaceutical Co Ltd
P2D Inc
Pacific Northwest Biotechnology LLC
Palisades Therapeutics
Park of Active Molecules
Passage Bio Inc
Plico Biotech Inc
Prediction BioSciences SAS
ProMIS Neurosciences Inc
Prothena Corp Plc
Psy Therapeutics Inc
PurMinds NeuroPharma Inc
QurAlis Corporation
Reata Pharmaceuticals Inc
Reborna Biosciences Inc
Resverlogix Corp
Reven Holdings Inc
Rubedo Life Sciences Inc
Sage Therapeutics Inc
Samus Therapeutics Inc
Shaperon Inc
Sinfonia Biotherapeutics Inc
Sio Gene Therapies Inc
SK Chemicals Co Ltd
SOLA Biosciences LLC
Stealth BioTherapeutics Corp
Stemedica Cell Technologies Inc
Sun Pharma Advanced Research Company Ltd
Suven Life Sciences Ltd
SyneuRx International Corp
T3D Therapeutics Inc
Targeted Pharmaceuticals LLC
TauRx Therapeutics Ltd
Teitur Trophics ApS
Theranexus SAS
Time Therapeutics Inc
Towa Pharmaceutical Co Ltd
Tranquis Therapeutics Inc
Transposon Therapeutics Inc
UCB SA
UniQure NV
Unity Biotechnology Inc
Vanqua Bio Inc
Vaxxinity Inc
Verge Genomics Inc
Voyager Therapeutics Inc
Wave Life Sciences Ltd
Whan In Pharm Co Ltd
Yumanity Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Dementia – Overview

Dementia – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Dementia – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Dementia – Companies Involved in Therapeutics Development

Dementia – Drug Profiles

Dementia – Dormant Projects

Dementia – Discontinued Products

Dementia – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Dementia, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Companies, 2022 (Contd..1)

Number of Products under Development by Companies, 2022 (Contd..2)

Number of Products under Development by Companies, 2022 (Contd..3)

Number of Products under Development by Companies, 2022 (Contd..4)

Number of Products under Development by Companies, 2022 (Contd..5)

Number of Products under Development by Companies, 2022 (Contd..6)

Number of Products under Development by Companies, 2022 (Contd..7)

Number of Products under Development by Companies, 2022 (Contd..8)

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022 (Contd..2)

Products under Development by Companies, 2022 (Contd..3)

Products under Development by Companies, 2022 (Contd..4)

Products under Development by Companies, 2022 (Contd..5)

Products under Development by Companies, 2022 (Contd..6)

Products under Development by Companies, 2022 (Contd..7)

Products under Development by Companies, 2022 (Contd..8)

Products under Development by Companies, 2022 (Contd..9)

Products under Development by Companies, 2022 (Contd..10)

Products under Development by Companies, 2022 (Contd..11)

Products under Development by Companies, 2022 (Contd..12)

Products under Development by Companies, 2022 (Contd..13)

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Target, 2022 (Contd..1)

Number of Products by Stage and Target, 2022 (Contd..2)

Number of Products by Stage and Target, 2022 (Contd..3)

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)

Number of Products by Stage and Mechanism of Action, 2022 (Contd..2)

Number of Products by Stage and Mechanism of Action, 2022 (Contd..3)

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Dementia – Pipeline by 2N Pharma ApS, 2022

Dementia – Pipeline by AbbVie Inc, 2022

Dementia – Pipeline by Acadia Pharmaceuticals Inc, 2022

Dementia – Pipeline by Actinogen Medical Ltd, 2022

Dementia – Pipeline by AcuraStem Inc, 2022

Dementia – Pipeline by Adamed Pharma SA, 2022

Dementia – Pipeline by ADEL Inc, 2022

Dementia – Pipeline by AFFiRiS AG, 2022

Dementia – Pipeline by AgeneBio Inc, 2022

Dementia – Pipeline by AIBIOS Co Ltd, 2022

Dementia – Pipeline by Alector Inc, 2022

Dementia – Pipeline by Alkermes Plc, 2022

Dementia – Pipeline by AlphaCognition Inc, 2022

Dementia – Pipeline by Alterity Therapeutics Ltd, 2022

Dementia – Pipeline by Alzamend Neuro Inc, 2022

Dementia – Pipeline by Amarantus Bioscience Holdings Inc, 2022

Dementia – Pipeline by Anavex Life Sciences Corp, 2022

Dementia – Pipeline by Anhorn Medicines Co Ltd, 2022

Dementia – Pipeline by Annovis Bio Inc, 2022

Dementia – Pipeline by Aphios Corp, 2022

Dementia – Pipeline by Applied Genetic Technologies Corp, 2022

Dementia – Pipeline by Aprinoia Therapeutics Inc, 2022

Dementia – Pipeline by Aptinyx Inc, 2022

Dementia – Pipeline by AriBio, 2022

Dementia – Pipeline by Arkuda Therapeutics Inc, 2022

Dementia – Pipeline by Arvinas Inc, 2022

Dementia – Pipeline by Asahi Kasei Pharma Corp, 2022

Dementia – Pipeline by Asceneuron SA, 2022

Dementia – Pipeline by AskAt Inc, 2022

Dementia – Pipeline by Astrogen Ltd, 2022

Dementia – Pipeline by Athira Pharma Inc, 2022

Dementia – Pipeline by AULBIO Co Ltd, 2022

Dementia – Pipeline by Aurum Biosciences Ltd, 2022

Dementia – Pipeline by Autifony Therapeutics Ltd, 2022

Dementia – Pipeline by Avanir Pharmaceuticals Inc, 2022

Dementia – Pipeline by AviadoBio Ltd, 2022

Dementia – Pipeline by Avineuro Pharmaceuticals Inc, 2022

Dementia – Pipeline by Avrion Therapeutics AG, 2022

Dementia – Pipeline by Axon Neuroscience SE, 2022

Dementia – Pipeline by Axsome Therapeutics Inc, 2022

Dementia – Pipeline by Bioasis Technologies Inc, 2022

Dementia – Pipeline by Biogen Inc, 2022

Dementia – Pipeline by Biom Therapeutics LLC, 2022

Dementia – Pipeline by Biorchestra Co Ltd, 2022

Dementia – Pipeline by BioXcel Therapeutics Inc, 2022

Dementia – Pipeline by CAMP4 Therapeutics Corp, 2022

Dementia – Pipeline by Cellivery Therapeutics Inc, 2022

Dementia – Pipeline by Cellular Biomedicine Group Ltd, 2022

Dementia – Pipeline by Cennerv Pharma (S) Pte Ltd, 2022

Dementia – Pipeline by Cerevel Therapeutics Holdings Inc, 2022

Dementia – Pipeline by ChunLab Inc, 2022

Dementia – Pipeline by Cogentis Therapeutics Inc, 2022

Dementia – Pipeline by Cognition Therapeutics Inc, 2022

Dementia – Pipeline by Cortice Biosciences Inc, 2022

Dementia – Pipeline by Coya Therapeutics Inc, 2022

Dementia – Pipeline by CSPC NBP Pharmaceutical Co Ltd, 2022

Dementia – Pipeline by CuraSen Therapeutics Inc, 2022

Dementia – Pipeline by Cyclerion Therapeutics Inc, 2022

Dementia – Pipeline by Dadang & BIO Co Ltd, 2022

Dementia – Pipeline by Daewoong Pharmaceutical Co Ltd, 2022

Dementia – Pipeline by Denali Therapeutics Inc, 2022

Dementia – Pipeline by DiaMedica Therapeutics Inc, 2022

Dementia – Pipeline by Dongkook Pharmaceutical Co Ltd, 2022

Dementia – Pipeline by Dr. August Wolff GmbH & Co KG Arzneimittel, 2022

Dementia – Pipeline by Echo Pharmaceuticals BV, 2022

Dementia – Pipeline by EIP Pharma LLC, 2022

Dementia – Pipeline by Eisai Co Ltd, 2022

Dementia – Pipeline by Eli Lilly and Co, 2022

Dementia – Pipeline by ENCEFA, 2022

Dementia – Pipeline by Ensol Biosciences Inc, 2022

Dementia – Pipeline by Enterin Inc, 2022

Dementia – Pipeline by EVER Neuro Pharma GmbH, 2022

Dementia – Pipeline by Expansion Therapeutics Inc, 2022

Dementia – Pipeline by Galimedix Therapeutics Ltd, 2022

Dementia – Pipeline by Generian Pharmaceuticals Inc, 2022

Dementia – Pipeline by Gismo Therapeutics Inc, 2022

Dementia – Pipeline by GraySpace Therapeutics Inc, 2022

Dementia – Pipeline by Guangzhou Magpie Pharmaceutical Co Ltd, 2022

Dementia – Pipeline by HanAll Biopharma Co Ltd, 2022

Dementia – Pipeline by Hemostemix Inc, 2022

Dementia – Pipeline by Herophilus, 2022

Dementia – Pipeline by HLB Pharmaceutical Co Ltd, 2022

Dementia – Pipeline by Hyundai Pharma Co Ltd, 2022

Dementia – Pipeline by IGC Pharma LLC, 2022

Dementia – Pipeline by Immungenetics AG, 2022

Dementia – Pipeline by ImStar Therapeutics Inc, 2022

Dementia – Pipeline by Inhibikase Therapeutics Inc, 2022

Dementia – Pipeline by Intra-Cellular Therapies Inc, 2022

Dementia – Pipeline by IntraBio Ltd, 2022

Dementia – Pipeline by Inventage Lab Inc, 2022

Dementia – Pipeline by Ionis Pharmaceuticals Inc, 2022

Dementia – Pipeline by IRLAB Therapeutics AB, 2022

Dementia – Pipeline by Jazz Pharmaceuticals Plc, 2022

Dementia – Pipeline by Johnson & Johnson, 2022

Dementia – Pipeline by KeifeRx LLC, 2022

Dementia – Pipeline by Kogenix Therapeutics Inc, 2022

Dementia – Pipeline by Korea Pharma Co Ltd, 2022

Dementia – Pipeline by Kuano Ltd, 2022

Dementia – Pipeline by Kwang Dong Pharmaceutical Co Ltd, 2022

Dementia – Pipeline by Lachesis Biosciences Ltd, 2022

Dementia – Pipeline by Locanabio Inc, 2022

Dementia – Pipeline by Luye Pharma Group Ltd, 2022

Dementia – Pipeline by MediPost Co Ltd, 2022

Dementia – Pipeline by Merck & Co Inc, 2022

Dementia – Pipeline by Merz Pharma GmbH & Co KgaA, 2022

Dementia – Pipeline by Metro International Biotech LLC, 2022

Dementia – Pipeline by MGC Pharmaceuticals Ltd, 2022

Dementia – Pipeline by MThera Pharma Co Ltd, 2022

Dementia – Pipeline by MYND Life Sciences Inc, 2022

Dementia – Pipeline by Neuramedy Co Ltd, 2022

Dementia – Pipeline by Neurimmune Holding AG, 2022

Dementia – Pipeline by Neurokine Therapeutics, 2022

Dementia – Pipeline by NeuroScientific Biopharmaceuticals Ltd, 2022

Dementia – Pipeline by NeuroTau Inc, 2022

Dementia – Pipeline by Neuvivo Inc, 2022

Dementia – Pipeline by NLS Pharmaceutics AG, 2022

Dementia – Pipeline by Novartis AG, 2022

Dementia – Pipeline by Novo Nordisk AS, 2022

Dementia – Pipeline by Oligomerix inc, 2022

Dementia – Pipeline by Orchard Therapeutics Plc, 2022

Dementia – Pipeline by Oryzon Genomics SA, 2022

Dementia – Pipeline by Otsuka Pharmaceutical Co Ltd, 2022

Dementia – Pipeline by P2D Inc, 2022

Dementia – Pipeline by Pacific Northwest Biotechnology LLC, 2022

Dementia – Pipeline by Palisades Therapeutics, 2022

Dementia – Pipeline by Park of Active Molecules, 2022

Dementia – Pipeline by Passage Bio Inc, 2022

Dementia – Pipeline by Plico Biotech Inc, 2022

Dementia – Pipeline by Prediction BioSciences SAS, 2022

Dementia – Pipeline by ProMIS Neurosciences Inc, 2022

Dementia – Pipeline by Prothena Corp Plc, 2022

Dementia – Pipeline by Psy Therapeutics Inc, 2022

Dementia – Pipeline by PurMinds NeuroPharma Inc, 2022

Dementia – Pipeline by QurAlis Corporation, 2022

Dementia – Pipeline by Reata Pharmaceuticals Inc, 2022

Dementia – Pipeline by Reborna Biosciences Inc, 2022

Dementia – Pipeline by Resverlogix Corp, 2022

Dementia – Pipeline by Reven Holdings Inc, 2022

Dementia – Pipeline by Rubedo Life Sciences Inc, 2022

Dementia – Pipeline by Sage Therapeutics Inc, 2022

Dementia – Pipeline by Samus Therapeutics Inc, 2022

Dementia – Pipeline by Shaperon Inc, 2022

Dementia – Pipeline by Sinfonia Biotherapeutics Inc, 2022

Dementia – Pipeline by Sio Gene Therapies Inc, 2022

Dementia – Pipeline by SK Chemicals Co Ltd, 2022

Dementia – Pipeline by SOLA Biosciences LLC, 2022

Dementia – Pipeline by Stealth BioTherapeutics Corp, 2022

Dementia – Pipeline by Stemedica Cell Technologies Inc, 2022

Dementia – Pipeline by Sun Pharma Advanced Research Company Ltd, 2022

Dementia – Pipeline by Suven Life Sciences Ltd, 2022

Dementia – Pipeline by SyneuRx International Corp, 2022

Dementia – Pipeline by T3D Therapeutics Inc, 2022

Dementia – Pipeline by Targeted Pharmaceuticals LLC, 2022

Dementia – Pipeline by TauRx Therapeutics Ltd, 2022

Dementia – Pipeline by Teitur Trophics ApS, 2022

Dementia – Pipeline by Theranexus SAS, 2022

Dementia – Pipeline by Time Therapeutics Inc, 2022

Dementia – Pipeline by Towa Pharmaceutical Co Ltd, 2022

Dementia – Pipeline by Tranquis Therapeutics Inc, 2022

Dementia – Pipeline by Transposon Therapeutics Inc, 2022

Dementia – Pipeline by UCB SA, 2022

Dementia – Pipeline by UniQure NV, 2022

Dementia – Pipeline by Unity Biotechnology Inc, 2022

Dementia – Pipeline by Vanqua Bio Inc, 2022

Dementia – Pipeline by Vaxxinity Inc, 2022

Dementia – Pipeline by Verge Genomics Inc, 2022

Dementia – Pipeline by Voyager Therapeutics Inc, 2022

Dementia – Pipeline by Wave Life Sciences Ltd, 2022

Dementia – Pipeline by Whan In Pharm Co Ltd, 2022

Dementia – Pipeline by Yumanity Therapeutics Inc, 2022

Dementia – Dormant Projects, 2022

Dementia – Dormant Projects, 2022 (Contd..1)

Dementia – Dormant Projects, 2022 (Contd..2)

Dementia – Dormant Projects, 2022 (Contd..3)

Dementia – Dormant Projects, 2022 (Contd..4)

Dementia – Dormant Projects, 2022 (Contd..5)

Dementia – Dormant Projects, 2022 (Contd..6)

Dementia – Discontinued Products, 2022

Dementia – Discontinued Products, 2022 (Contd..1)

Figures

List of Figures

Number of Products under Development for Dementia, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

Dementia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,500

Can be used by individual purchaser only

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Dementia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Dementia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.